NTX 010

Drug Profile

NTX 010

Alternative Names: NTX-010; Seneca Valley Virus-001; SVV-001

Latest Information Update: 04 Jun 2015

Price : $50

At a glance

  • Originator Novartis
  • Developer National Cancer Institute (USA); Neotropix; North Central Cancer Treatment Group
  • Class Antineoplastics; Oncolytic viruses
  • Mechanism of Action Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Neuroendocrine tumours; Small cell lung cancer

Most Recent Events

  • 31 May 2013 Safety and efficacy data from a phase II trial in Small cell lung cancer presented at the 49th Annual Meeting of the American Society of Clinical Oncology
  • 23 Feb 2010 Neotropix completes enrolment in its Phase-I trial (NCT00314925) for Neuroendocrine tumours in USA
  • 19 Apr 2009 Preclinical pharmacodynamics data presented at the 100th Annual Meeting of the American Association for Cancer Research (AACR-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top